Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$76.95

1.12 (1.48%)

, CVS

CVS Health

$80.90

0.83 (1.04%)

08:15
10/06/17
10/06
08:15
10/06/17
08:15

Leerink convinced Amazon entering drug distribution within two years

After calls with pharmacy benefit managers and retail pharmacy specialists, Leerink analyst Ana Gupte says she's convinced that Amazon.com (AMZN) "will almost certainly" enter the drug distribution value chain within two years, evolving into a more disruptive offering over time. Amazon's move is most threatening for retail pharmacies Walgreens Boots Alliance (WAB), CVS Health (CVS) and Wal-Mart (WMT), Gupte tells investors in a research note. The analyst calls Amazon both an opportunity and threat for Express Scripts (ESRX) and views UnitedHealth (UNH) and Humana (HUM) as "largely buffered." Gupte's conversations with specialists indicate Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. It is believed Amazon will start by capturing share in both the cash paying and third party mail order and possibly specialty pharmacy segments, Gupte notes. She expects Anthem (ANTM), Aetna (AET) and Cigna (CI) will likely to contemplate Amazon's entry in their upcoming PBM contract decisions.

WBA

Walgreens Boots Alliance

$76.95

1.12 (1.48%)

CVS

CVS Health

$80.90

0.83 (1.04%)

WMT

Wal-Mart

$79.41

0.32 (0.40%)

ESRX

Express Scripts

$64.01

0.03 (0.05%)

UNH

UnitedHealth

$197.90

-2.58 (-1.29%)

HUM

Humana

$245.36

-1.15 (-0.47%)

AMZN

Amazon.com

$980.85

15.4 (1.60%)

ANTM

Anthem

$192.92

-0.5 (-0.26%)

AET

Aetna

$161.29

-1.92 (-1.18%)

CI

Cigna

$190.68

-0.07 (-0.04%)

  • 08

    Oct

  • 10

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

  • 25

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

WBA Walgreens Boots Alliance
$76.95

1.12 (1.48%)

09/27/17
09/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Market Perform at Raymond James with analyst John Ransom saying Walgreens' premium valuation is not warranted and prefers Outperform rated CVS (CVS) given challenging relative comps, a weakening industry backdrop with flat FE sales and moderating Rx trends, modest accretion from the Rite Aid (RAD) acquisition, lack of further cost cutting actions, slightly larger exposure to Puerto Rico and Florida, and UK exposure, among other reasons. 2. trivago (TRVG) downgraded to Neutral from Overweight at JPMorgan with analyst Doug Anmuth saying the shares could be range-bound for a longer period of time as the company works through bidding adjustments from large advertisers like Priceline (PCLN) and rolls out its performance attribution model. 3. Tile Shop (TTS) downgraded to Neutral from Overweight at Piper Jaffray analyst Peter Keith citing concerns of another comp and earnings miss for third quarter as well as potential for a full year guide-down. 4. Intuit (INTU) downgraded to Underperform from Market Perform at Raymond James with analyst Wayne Johnson citing concerns the tax business is becoming more challenging to grow and maintaining 60% operating margin will be difficult. 5. Kornit Digital (KRNT) downgraded to Neutral from Buy at Citi with analyst Kenneth Wong saying customer delays worsened after the company announced preliminary revenue well below its previous guidance range. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
JEFF
10/02/17
NO CHANGE
Target $95
JEFF
Buy
Walgreens growth from Rite Aid stores not priced in, says Jefferies
Jefferies analyst Brian Tanquilut says he remains positive on Walgreens Boots Alliance (WBA) given his expectation for sustained double-digit earnings growth over the next few years. The acquisition of Rite Aid (RAD) stores will yield incremental earnings growth in the next few years that's not yet priced into the stock, Tanquilut tells investors in a research note. He believes that while Amazon (AMZN) risk to front-end pharmaceutical sales "is real," Walgreens has done better than peers in "weathering the storm." The analyst has a Buy rating on the shares with a $95 price target.
10/06/17
MSCO
10/06/17
DOWNGRADE
MSCO
Equal Weight
Walgreens Boots Alliance downgraded to Equal Weight at Morgan Stanley
10/06/17
10/06/17
DOWNGRADE
Target $85

Equal Weight
Walgreens downgraded to Equal Weight from Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Ricky Goldwasser downgraded Walgreens Boots Alliance to Equal Weight from Overweight, as he expects the company's guidance to come in below consensus estimates when it is provided later this month. The key drivers he cites are recent Part D preferred network exclusions, as well as reimbursement cuts in the U.K. and reimbursement pressure in the U.S. Goldwasser, who notes the company's growth is slowing, cut his price target on Walgreens shares to $85 from $95.
CVS CVS Health
$80.90

0.83 (1.04%)

08/28/17
NEED
08/28/17
NO CHANGE
NEED
Amazon, Whole Foods combined company not an incremental competitor, says Needham
Needham analyst Kevin Caliendo notes that drug retailers were weak after Amazon (AMZN) said it would provide its Prime members enhanced benefits while shopping at newly acquired Whole Foods (WFM) and cut prices on certain household staple items inside the grocer. While the analyst understands the Amazon threat will remain for the drug retailers and pharma supply chain, he believes the news should have no material impact on revenues or profits at CVS Health (CVS) and Walgreens Boots Alliance (WBA). Caliendo expects that Amazon will continue to try and lever its website and Whole Foods store locations to increase traffic, but he does not yet see the combined company as an incremental competitor beyond what each did separately.
09/19/17
09/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Underperform at Jefferies. 2. DowDuPont (DWDP) initiated with a Buy at Argus. 3. Intuit (INTU) initiated with an Outperform at William Blair. 4. CVS Health (CVS) initiated with an Outperform at RBC Capital. 5. athenahealth (ATHN) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/17
LEER
09/14/17
NO CHANGE
LEER
Minimal hurricane exposure for pharma supply chain, says Leerink
Leerink analyst David Larsen sees less than 1% impact to revenues and earnings to companies in his coverage from Hurricane Harvey and Irma and believes any effects will be viewed as one-time in nature. The analyst notes that "the percentage of state impacted" and "days of impact" are particularly challenging variables in his model to estimate, but based on various assumptions he believes the hurricanes will prove to be a minor event for Express Scripts (ESRX), AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK). Nonetheless, Larsen says pharmacy retailers Walgreens Boots Alliance (WBA) and CVS Health (CVS) may face some store closures and possible damage costs.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Outperform
CVS Health initiated with an Outperform at RBC Capital
RBC Capital analyst George Hill started coverage of CVS with a $95 price target and an Outperform rating. He thinks that the company "could transform itself" by merging with a health insurance company, although he says that the chances of such a deal are "low." He estimates that such a deal could increase the company's EPS by over 10% and cause its multiple to rise by 200%-400%. Hill says that the stock's valuation is attractive even if the company does not make a deal.
WMT Wal-Mart
$79.41

0.32 (0.40%)

09/06/17
FBCO
09/06/17
NO CHANGE
Target $43
FBCO
Underperform
Campbell Soup, Wal-Mart still negotiating, says Credit Suisse
Following up on Campbell Soup's (CPB) public disagreement in the soup category with Wal-Mart (WMT), Credit Suisse analyst Robert Moskow says the dispute specifically relates to Wal-Mart's demands for lower everyday price points on Campbell's condensed soup products. While this dispute does not appear to involve General Mills' (GIS) Progresso brand or the ready-to-serve category at this time, the analyst notes that Wal-Mart presumably could threaten to give more shelf space to General Mills or its Great Value brand at Campbell's expense. Campbell and Wal-Mart are still negotiating, Moskow points out, adding that it may be a good thing for the stock if Campbell can get Wal-Mart to agree to a compromise. The analyst reiterates an Underperform rating and $43 price target on Campbell's shares.
08/29/17
OPCO
08/29/17
NO CHANGE
OPCO
Whole Foods price cuts deep, not broad yet after Amazon deal, says Oppenheimer
Based on his analysis in New York City following Amazon (AMZN) acquisition, Oppenheimer analyst Rupesh Parikh notes Whole Foods (WFM) cut prices on select items by 22%, or $1.15 on average. The analyst would characterize Whole Foods' cuts as deep, but not broad yet. Parikh expects a heightened period of volatility for grocers to persist given competitive uncertainty, and says he does not expect Wal-Mart (WMT) and Kroger (KR) to let pricing gaps erode. As a result, the analyst would expect counter-reactions if need be to the extent Amazon gets aggressive on a basket of items versus just a few SKUs.
09/07/17
WELS
09/07/17
NO CHANGE
WELS
Market Perform
Perrigo signaled willingness to work with Amazon, says Wells Fargo
Wells Fargo analyst David Maris noted that while presenting yesterday at the firm's conference, Perrigo (PRGO) said it would welcome working with Amazon on store brands. Currently, online sales partnerships with e-commerce arms of existing retailers, such as Walmart (WMT) and Walgreens (WBA), account for 1% of Perrigo products, he added. Maris, who said the company made an "upbeat and confident presentation," keeps a Market Perform rating on Perrigo shares.
09/20/17
KEYB
09/20/17
NO CHANGE
KEYB
Toys R Us bankruptcy positive for Wal-Mart, Amazon, says KeyBanc
KeyBanc analyst Edward Yruma views the Toys R Us (TOY) bankruptcy as positive for both Wal-Mart (WMT) and Amazon (AMZN). The analyst believes that Wal-Mart's toy and baby business is over two times Toys R Us' domestic business and that its relative importance to the toy companies will only increase. Meanwhile, Yruma thinks Amazon's growth and convenience will drive continued share gains as well.
ESRX Express Scripts
$64.01

0.03 (0.05%)

07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
06/27/17
BARD
06/27/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy and entire supply chain have reimbursement risk, says Baird
Baird analyst Eric Coldwell noted Diplomat Pharmacy (DPLO) shares were lower yesterday based on a competitor's research note that suggested Express Scripts (ESRX) was cutting reimbursement in certain commercial plans and is kicking the tires on a DIR rollout in Part D. The analyst believes that would be not only negative for Diplomat but for all in the supply chain. The fact that others were not hit as hard is confusing to Coldwell, but he hopes for clarification from the company's IR day tomorrow. Coldwell maintained his Outperform rating and $20 price target on Diplomat Pharmacy shares.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Express Scripts initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Express Scripts (ESRX) with a $68 price target and a Sector Perform rating. The analyst says that the company "faces an uncertain future" in the wake of the loss of its deal with Anthem ( ANTM), as he believes that it will have difficulty generating operating profit growth without Anthem.
UNH UnitedHealth
$197.90

-2.58 (-1.29%)

08/30/17
ADAM
08/30/17
DOWNGRADE
Target $54
ADAM
Hold
The Advisory Board downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
08/29/17
PIPR
08/29/17
NO CHANGE
Target $54.29
PIPR
Neutral
Piper says Advisory Board deal should be marginally accretive to UnitedHealth
Piper Jaffray analyst Sean Wieland said Advisory Board's (ABCO) deal to merge its healthcare business with United Healthcare's (UNH) OptumInsights should be marginally accretive to UnitedHealth and add to his confidence in his FY18 OptumInsights growth estimates. He keeps a Neutral rating on Advisory Board shares and raised his price target on the stock to $54.29 from $51 to reflect the combined estimated amount being paid to shareholders by Optum and Vista Equity, the buyers of Advisory's education business.
08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Overweight
UnitedHealth made 'solid choice' in new CEO, says Piper Jaffray
Piper Jaffray analyst Sarah James views UnitedHealth's promotion of David Wichmann as a "solid choice and not a surprise." The analyst expects business as usual for the company as it continues to push into technology including artificial intelligence. She has an Overweight rating on the shares.
10/02/17
BERN
10/02/17
NO CHANGE
BERN
Bernstein does not anticipate ACA fix/repeal before 2018 election
While noting the resignation of Health Secretary Tom Price, Bernstein analyst Lance Wilkes says he does not anticipate an Affordable Care act fix or ACA repeal before the 2018 election. The analyst expects tax reform will "suck the oxygen out of the room" until close to the election. A fix for 2019 is possible, but faces the headwind of the 2018 election campaign, he contends, adding that he believes CSR funding could be included in a trade for the upcoming budget and the Health Insurance Fee could be suspended as part of tax reform, but both are not highly likely at this point. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$245.36

-1.15 (-0.47%)

08/03/17
FBCO
08/03/17
NO CHANGE
Target $260
FBCO
Outperform
Humana price target raised to $260 from $250 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $260 from $250 following quarterly results. The analyst reiterates an Outperform rating on the shares.
08/03/17
PIPR
08/03/17
NO CHANGE
Target $280
PIPR
Overweight
Humana price target raised to $280 from $246 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Humana to $280 saying the company reported a "strong" beat and raise quarter driven by "strong" Medicare Advantage performance and improved cost control. The analyst sees upside to the current share price and keeps an Overweight rating on Humana.
08/03/17
OPCO
08/03/17
NO CHANGE
Target $255
OPCO
Outperform
Humana price target raised to $255 from $236 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $255 from $236 following "strong results" that were driven by outperformance in Medicare Advantage, and after the company raised 2017 EPS guidance. The analyst reiterates an Outperform rating on the shares.
AMZN Amazon.com
$980.85

15.4 (1.60%)

10/06/17
BARD
10/06/17
NO CHANGE
BARD
Amazon implications negative for FedEx, UPS, says Baird
Baird analyst Benjamin Hartford noted reports Amazon (AMZN) is testing its own final mile delivery service in the U.S. and he believes it is a logical extension of its model as it builds network density. The analyst believes the implications for parcel providers FedEx (FDX) and UPS (UPS) are negative, as it could put pressure on delivery rates and volume may be diverted from both. Hartford continues to rate FedEx with an Outperform and $235 price target and UPS remains Neutral rated with a $125 price target.
10/06/17
RILY
10/06/17
NO CHANGE
Target $250
RILY
Buy
Amazon's Seller Flex expansion unlikely to impact Stamps.com, says B. Riley
B. Riley analyst Kevin Liu believes Amazon.com's (AMZN) plans to expand its Seller Flex program more broadly in 2018 following a two-year pilot in India and testing in West Coast states, as reported yesterday by Bloomberg, is unlikely to impact Stamps.com (STMP). The Seller Flex program Seller Flex arranges for the pickup and delivery of merchandise from the seller's distribution facility, which could potentially impact volumes currently routed through the major domestic carriers, Liu tells investors in a research note. He believes FedEx (FDX) and UPS (UPS) have the most to lose given their exposure to large shippers. The analyst sees "little risk at present" to Stamps.com given that Seller Flex is targets merchants with a "far greater" assortment, order volumes, and logistical footprint than is typically targeted by the company's various brands. Liu reiterates a Buy rating on Stamps.com with a $250 price target.
10/05/17
CLVD
10/05/17
NO CHANGE
CLVD
Wayfair in focus as Amazon to compete in furniture category, says Cleveland
Cleveland Research said Wayfair (W) continues to perform well and remains an industry leader in the furniture category but believes Amazon (AMZN) has invested significantly in recent years to compete more effectively in the furniture category over the long-term. The firm's analyst has heard Amazon has added eight freight companies for heavy/bulk inventory since the beginning of the year to improve its furniture offering and is targeting Wayfair given its growth of 50% in 2016 with sales reaching $3.4B.
10/05/17
DBAB
10/05/17
NO CHANGE
DBAB
Deutsche calls Bloomberg headline on Amazon rivaling UPS, FedEx misleading
The headline of Bloomberg's story this morning on Amazon titled "Amazon Is Said to Test Own Delivery Service to Rival FedEx, UPS" is misleading, Deutsche Bank analyst Amit Mehrotra tells investors in a research note. Amazon's initiates are aimed at growing its own volumes to lower unit shipment costs, the analyst contends. He does not find it likely that Amazon at this point will invests heavily in its own network for last mile business-to-consumer deliveries. FedEx (FDX) in early trading is down $1.01 to $220.31 while UPS (UPS) is down $1.42 to $117.58.
ANTM Anthem
$192.92

-0.5 (-0.26%)

06/28/17
SBSH
06/28/17
NO CHANGE
Target $205
SBSH
Buy
Anthem removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Anthem (ANTM) from his firm's Focus List but keeps a Buy rating on the shares with a $205 price target. The analyst believes some of the upside catalysts have played out. He also added Aetna (AET) to the Focus List.
07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
AET Aetna
$161.29

-1.92 (-1.18%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $165
FBCO
Outperform
Aetna price target raised to $165 from $160 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Aetna to $165 from $160 ahead of Q2 results. He reiterates an Outperform rating on the shares.
07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
09/12/17
ARGS
09/12/17
NO CHANGE
ARGS
Aetna price target raised to $185 from $165 at Argus
Argus analyst David Toung believes that Aetna reported "strong" Q2 results. The analyst remains upbeat on the company's 2H17 outlook and keeps a Buy rating on the shares.
CI Cigna
$190.68

-0.07 (-0.04%)

06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.